TNFRSF8 and T-cell non-Hodgkin lymphoma: Our findings demonstrate the feasibility of this protocol, as generated MU-CAR-T cells are successfully validated for their target recognition and cytotoxicity mediated by VRC01-scFv or CD5-CD30 scFvs for latent HIV-1-infected cells or T cell lymphoma cells respectively.